Bristol-Myers Squibb Company (BMY) Stock
NYSEBMY has an Alpha Score of 61 out of 100 (moderate), computed on Nov 2, 2026 from 3 of 4 sub-scores. 37 members of Congress disclosed 103 trades in BMY since 2014: 43 purchases and 59 sales, most recently Mike Kelly (sale, May 7, 2026). 5 of the hedge funds AlphaScala tracks reported BMY in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $90.60M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 13.4 and its net margin 18.9% (key statistics as of Oct 22, 2026).
What is BMY's Alpha Score?
How it works →Alpha Score of 61 reflects moderate overall profile with moderate momentum, strong value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 2, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Bristol-Myers Squibb Company (BMY)?
Most recent: Mike Kelly (sale, May 7, 2026); records start Feb 5, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Mike Kelly R-PA · House | 2026-05-07 | sale | $15k – $50k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-12-19 | purchase | $1k – $15k |
| Julie Johnson D-TX · House | 2025-12-18 | sale | $1k – $15k |
| Julie Johnson D-TX · House | 2025-11-13 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-11-12 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-10-09 | partial sale | $1k – $15k |
| Julie Johnson D-TX · House | 2025-08-14 | partial sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded BMY, with filing lags →Which hedge funds own BMY?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.57M | $90.60M | +5% |
| Millennium Management Israel Englander | 753K | $43.36M | -89% |
| D.E. Shaw David Shaw | 559K | $32.23M | +81% |
| Marshall Wace | 15K | $874.0K | -100% |
| Blackstone | 9K | $520.8K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Bristol-Myers Squibb Company insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 9, 26 | Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | SELL | 6.2K | $403K |
| Aug 25, 26 | Holzer Phil M | SVP and Controller | SELL | 500 | $34K |
| Apr 1, 26 | Elkins David V | EVP, Chief Financial Officer | SELL | 25.5K | $1.6M |
| Apr 1, 26 | Elkins David V | EVP, Chief Financial Officer | SELL | 4.5K | $278K |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are BMY's key statistics?
Key statistics as of Oct 22, 2026
How does BMY's valuation compare with the Healthcare sector?
| Metric | BMY | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 13.4 | 27.1 | 97 |
| Net margin | 18.87% | 5.48% | 139 |
| Return on equity | 46.76% | 6.84% | 158 |
| Dividend yield (payers) | 4.58% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
BMY price chart
Powered by TradingViewWhat does Bristol-Myers Squibb Company do?
Bristol-Myers Squibb Company is a global biopharmaceutical firm founded in 1887 that discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines worldwide. Its portfolio addresses critical therapeutic areas including oncology, hematology, immunology, cardiovascular disease, neuroscience, and other medical needs. Key products include Eliquis, which reduces the risk of stroke and systemic embolism in non-valvular atrial fibrillation and treats deep vein thrombosis and pulmonary embolism; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for rheumatoid arthritis and psoriatic arthritis; and Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia. With approximately 34,100 employees and headquarters in New York, the company generates substantial revenue, reporting trailing twelve-month figures of US$48.03 billion alongside earnings of US$6.04 billion. Bristol-Myers Squibb Company plays a pivotal role in advancing healthcare through its focus on high-unmet-need diseases, contributing to the pharmaceutical industry's efforts in oncology and immunology while maintaining strong financial health evidenced by robust gross margins and dividend capabilities.